Objectives-Coronary reperfusion has been the mainstay therapy for reduced infarct size after a heart attack. However, this intervention also results in myocardial injury by initiating a marked inflammatory reaction, and new treatments are keenly sought. Methods and Results-The basic-region leucine zipper protein, c-Jun is poorly expressed in the normal myocardium and is induced within 24 hours after myocardial ischemia-reperfusion injury. Synthetic catalytic DNA molecules (DNAzymes) targeting c-Jun (Dz13) reduce infarct size in the area-at-risk (AAR) regardless of whether it is delivered intramyocardially at the initiation of ischemia or at the time of reperfusion. Dz13 attenuates neutrophil infiltration, c-Jun and ICAM-1 expression in vascular endothelium, cardiomyocyte apoptosis, and the generation of reactive oxygen species in the reperfused myocardium. It inhibits infiltration into the AAR of complement 3 (C3), C3a receptor (C3aR), membrane attack complex-1 (Mac-1), or matrix metalloproteinase-2 (MMP-2) positive inflammatory cells. Dz13 also improves cardiac function without influencing myocardial vascularity or fibrosis. 
O utcomes after acute myocardial infarction (AMI) have improved markedly over the past decades, but unmet challenges remain. Although restoration of blood flow to the ischemic myocardium with primary percutaneous coronary intervention or thrombolytic therapy has been shown effective in reducing infarct size, these interventions can also result in cardiomyocyte injury by initiating marked inflammation. The pathophysiology of myocardial/ischemiareperfusion (M/IR) injury is complex and involves the production and release of surface adhesion molecules and other inflammatory mediators, including intercellular adhesion molecule-1 (ICAM-1), reactive oxygen species (ROS), and activation of the complement system. For drugs to effectively attenuate this response, they would need to have broadspectrum activity to inhibit the multiple pathways and limit their cross-amplification.
c-Jun, a 39-kDa basic-region leucine zipper protein and prototypic member of the activating protein-1 (AP1) family of transcription factors, is activated by multiple stimuli including inflammatory cytokines. 1, 2 Deletion of c-jun in mice results in embryonic lethality. 3 Studies have shown the activation of AP1 as early as 15 minutes after reperfusion 4 and that decreased c-Jun phosphorylation correlates with reduced infarct size. 5 We have demonstrated that knockdown of c-Jun by RNA-cleaving catalytic agents, termed DNAzymes, 6 suppress vascular permeability and transendothelial emigration of leukocytes in various rodent inflammatory models including cytokine-challenged mesenteric venules, endotoxin-induced lung sepsis, and collagen antibody-induced rheumatoid arthritis. 2 Reperfusion injury after AMI involves degradation of extracellular matrix components by matrix metalloproteinases (MMPs), ROS production, apoptosis, and activation of the complement system. 7 Complement activation is associated with neutrophil infiltration and increased myocardial infarct size as a consequence of ischemic cardiac damage after the reperfusion. 8 Activation of the complement system produces tissue injury through formation of the membrane attack complex Mac-1 (C5b-9), which causes cell death through disruption of cellular integrity. 9 The anaphylatoxin C3a is a proinflammatory mediator generated during complement activation 10 and exerts its effects via the heptahelical receptor C3aR, 11 which is expressed on leukocytes and endothelial cells. 12, 13 AP1 regulates the C3aR promoter in monomyeloblastic U937 cells. 14 The C3b receptor, the CD11c leukocyte integrin, which mediates neutrophil adher-ence, 15 is also activated by AP1. 16 C3b deposition in endothelial cells is ameliorated by ROS scavengers that interfere with the production of free radicals. 17 M/IR injury is reduced in experimental models and certain clinical settings through blockade of the complement system by C1 esterase inhibition or sC1R and anti-C5a therapy. 18 It is also well recognized that left ventricular remodeling and myocardial dysfunction after M/IR injury are mediated by MMPs, particularly MMP-2. 19 Other studies by our group have demonstrated that Dz13 suppresses solid tumor growth in part by inhibiting MMP-2 expression. 20, 21 These findings have made the complement system, MMPs, and cell adhesion molecules a focus of interventional approaches in the setting of AMI.
Here we hypothesized that molecular suppression of c-Jun, as a master regulator of these and other proinflammatory genes, may protect the myocardium from ischemia-reperfusion injury.
Methods
For details of cell culture and transfection, M/IR injury model, tissue collection, and measurement of infarct size and inflammatory cell infiltration, RT-PCR, neutrophil counts, immunohistochemistry and TUNEL staining, and statistical analysis, please see supplemental material (available online at http://atvb.ahajournals.org).
Results

Dz13 Reduces Myocardial Infarct Size in the Area-at-Risk Regardless of Whether It Is Delivered Intramyocardially at the Initiation of Ischemia or at the Time of Reperfusion
To determine the influence of c-Jun suppression on infarct size in the area-at-risk (AAR), Dz13 or Dz13scr was administered by intramyocardial (IM) injection at 4 sites within the AAR in the left ventricle (LV). Infarct size and the AAR were determined by Evans blue exclusion and triphenyl tetrazolium chloride (TTC) staining, respectively. These experiments involved DNAzyme delivery at 2 separate times relative to ischemia-reperfusion: the first, at the commencement of ischemia, and the second, at the time of reperfusion. Representative LV slices from Dz13 or Dz13scr cohorts 24 hours after the drug was administered at the time the LCA was ligated are shown in Figure 1A . Ischemia-reperfusion with no injection (No ODN, No Veh) or IM injection of vehicle control (No ODN) resulted in a mean infarct size occupying approximately 32% of the AAR ( Figure 1B) . Administration of Dz13 at the start of ischemia inhibited infarct size by 55%. When Dz13 was delivered at the time of reperfusion, a 43% reduction in infarct size was achieved relative to the vehicle and scrambled groups ( Figure 1C ). No differences in AAR were observed between groups, indicating surgical consistency in both models ( Figure 1D and 1E).
Dz13 Attenuates Neutrophil Infiltration in the Reperfused Myocardium
Twenty-four hours after ischemia-reperfusion, the infarcted myocardium loses its regular structure and will have had significant inflammatory cell infiltration. Previous studies have shown that many of these infiltrating cells are morphologically-distinct polymorphonuclear leukocytes (neutrophils). 22 Compared with vehicle (No ODN) and Dz13scr groups, Dz13 caused a 50% reduction in neutrophil infiltration in the reperfused myocardium ( Figure 1F ). Immunofluorescence microscopy confirmed delivery of FITClabeled DNAzyme (FITC-Dz) into cells of the AAR (data not shown).
Dz13 Inhibits c-Jun and ICAM-1 Expression in Vascular Endothelium
The preceding data implicate c-Jun, the primary target of Dz13 in the control of myocardial infarct size ( Figure ICAM-1 is a well-recognized mediator of the early interaction and adhesion of neutrophils to coronary endothelial cells and myocytes after M/IR injury. 23 Because Dz13 reduced neutrophil infiltration in the ischemia-reperfused myocardium, we examined the effect of Dz13 on ICAM-1 expression. IHC analysis revealed that Dz13 attenuated M/IR-inducible ICAM-1 expression in the blood vessels, whereas Dz13scr had no inhibitory effect ( Figure 2B ).
Dz13 Inhibits Cardiomyocyte Apoptosis in the Injured Myocardium
We next assessed the effect of Dz13 on apoptosis induced by M/IR in the AAR. Terminal deoxynucleotidyl transferasemediated dUTP nick-end labeling (TUNEL) 24 hours after M/IR identified apoptotic nuclei in cardiomyocytes ( Figure 2C ). Dz13 inhibited TUNEL ϩ staining in the AAR ( Figure 2C ), consistent with its ability to reduce infarct size ( Figure 1A through 1E), whereas Dz13scr had no effect ( Figure 2C ).
Dz13 Inhibits Cytokine-Inducible Components of the Complement System
Although it is known that AP1 regulates transcription of the anaphylatoxin C3a receptor, C3aR, 14 whether c-Jun/AP1 controls other components of the complement system is unclear. We overexpressed c-Jun using a RSV-based expression vector in human umbilical vein endothelial cells (HUVECs) and evaluated mRNA levels after 24 hours. c-Jun transcript levels, barely detectable in growth-quiescent cells, were increased following transfection with the c-Jun vector (supplemental Figure IA) . c-Jun increased levels of C3 mRNA without affecting levels of ␤actin (supplemental Figure IA) . Dz13 blocked both c-Jun expression in cells transfected with the plasmid and c-Jun-inducible C3 mRNA expression (supplemental Figure IA) . In contrast, Dz13scr had no effect on c-Jun or C3 mRNA levels induced by the expression vector (supplemental Figure IA) . To demonstrate the dependence on c-Jun of cytokine-inducible C3, C3aR, and C5, we exposed HUVECs to IL-1beta for 2 hours with or without prior Dz13 or Dz13scr transfection. IL-1beta stimulated c-Jun mRNA expression, as it did levels of C3 C3aR and C5, without affecting ␤-actin expression (supplemental Figure IB) . Dz13 abolished the cytokine-inducible expression of these components of the complement system (supplemental Figure IB ). C3 mRNA, like c-Jun, is poorly expressed in the AAR, but increased after M/IR (supplemental Figure IC) . Dz13 reduced M/IR-inducible C3 and c-Jun expression, whereas Dz13scr had no effect (supplemental Figure IC) .
Dz13 Reduces Density of C3, C3aR, and Mac-1-Positive Cells in the Injured Myocardium
IHC analysis revealed that C3 is expressed in the myocardial microvasculature and macrophages, the latter cell type identified by MAC-3 immunostaining (supplemental Figure IIA) . Dz13 suppressed M/IR-inducible C3 expression in the endothelium (supplemental Figure IIA) . It also reduced the population of C3 ϩ macrophages in the AAR (supplemental Figure IIA) . C3aR was inducibly expressed in macrophages, cardiomyocytes, and blood vessels (supplemental Figure  IIB) . Dz13 also reduced endothelial C3aR ϩ staining and density of C3aR ϩ cells in the AAR, whereas Dz13scr had no effect (supplemental Figure IIB) . Mac-1 (C5b-9) staining, like that of C3 and C3aR, was virtually undetectable in the LV of sham-treated animals, but was readily detectable after M/IR injury (supplemental Figure IIC) . Mac-1 ϩ staining was confined primarily to macrophages, which were identified by MAC-3 staining (supplemental Figure IIC) .
Dz13 Reduces Density of MMP-2-Positive Cells in the Injured Myocardium
LV remodeling and myocardial dysfunction after M/IR injury are mediated by MMPs, particularly MMP-2. 19,24 -26 MMP-2 has also recently been shown to mediate M/IR injury by enhanced peroxynitrite biosynthesis during early reperfusion. 27 MMP-2 is produced in the human heart after AMI. 28 Dz13 inhibited M/IR-inducible MMP-2 mRNA expression in the AAR (supplemental Figure IIC) . IHC revealed that Dz13 reduced MMP-2 levels in endothelial cells, consistent with our previous findings in nonmyocardial tissue, 2, 20, 21, 29 and the density of MMP-2 ϩ macrophages in the AAR (supplemental Figure IID) .
Dz13 Attenuates ROS Generation
Nitrotyrosine is an established "footprint" of peroxynitrite, 30 a toxic ROS produced by invading neutrophils. We reasoned that increased nitrotyrosine levels would coincide with neutrophil infiltration into the AAR of the LV and that this would be negatively regulated by Dz13. Nitrotyrosine levels, like those of c-Jun (Figure 2A ), were negligible in sham-operated animals but increased 24 hours after M/IR injury ( Figure 3) . Nitrotyrosine was inducibly expressed in both macrophages and cardiomyocytes (Figure 3 ) in the AAR. Dz13 suppressed nitrotyrosine immunoreactivity compared with Dz13scr and vehicle groups (Figure 3 ).
Dz13 Improves Function After M/IR Injury and Does Not Influence Myocardial Vascularity or Fibrosis in the AAR
Finally, to determine the effect of Dz13 on cardiac function after M/IR injury and demonstrate the clinical relevance of our findings, we measured ejection fraction (EF) and fractional shortening (FS) in DNAzyme-treated and untreated rats using VisualSonics' Vevo 770 high-resolution microultrasound imaging system. EF and FS were both reduced 24 hours after M/IR injury ( Figure 4B ). The decline in myocardial function was protected by Dz13 but not by Dz13scr ( Figure 4B ). Vascularity in the AAR was examined in animals subjected to M/IR injury 14 days after reperfusion by immunostaining and quantitating vWF positive vessels. No difference was observed in microvascular density between the 2 groups ( Figure 4B and 4C) . Moreover, comparison of Masson trichrome-stained sections of the AAR between Dz13 and Dz13scr-treated groups revealed no difference in the extent of fibrosis ( Figure 4D and 4E ).
Discussion
The data in this manuscript provide several novel findings. First, c-Jun regulates cytokine-inducible components of the complement system (supplemental Figure I) . Second, a single dose of Dz13, delivered locally into the myocardium, reduces infarct size in the AAR irrespective of whether it is injected at the start of ischemia or at the time of reperfusion ( Figure  1A through 1E) . Third, Dz13 inhibits neutrophil infiltration Reduced myocardial infarct size after treatment with Dz13 is likely the consequence of DNAzyme blockade of a variety of c-Jun-dependent molecular and cellular processes. As this study shows, M/IR triggers the expression of numerous proinflammatory mediators including cell adhesion molecules, components of the complement system, and ROS. Dz13 clearly exerts its effects not through a single pathway, but rather multiple pathways, by targeting the "master regulator" c-Jun. Consistent with reduced neutrophil infiltration as a consequence of Dz13 treatment, we observed reduced ICAM-1, C3, and Mac-1 expression. All these molecules regulate neutrophil infiltration. ICAM-1 mediates neutrophil adhesion to vascular endothelium and transendothelial migration of leukocytes into the myocardial interstitium. Inhibition of neutrophil infiltration by reducing ICAM-1 expression by Dz13 is supported by our recent observations of Dz13 blockade of ICAM-1 expression in murine models of lung, joint, and venular inflammation. 2 Complement components C3 and Mac-1 are thought to regulate neutrophil-mediated myocardial injury via several mechanisms. Mac-1 may upregulate CD62P on endothelial cells, resulting in increased neutrophil adherence. 31 Sublytic amounts of Mac-1 have been shown to induce MCP-1 and IL-8 in endothelial cells. 32 Increased ICAM-1 expression may be modulated by C3a expressed by leukocytes and endothelial cells. 33, 34 Moreover, C3b deposition on endothelial cells may mediate neutrophil adhesion via CD11b/CD18 interactions. Reduced MMP-2 mRNA and protein expression by Dz13 as demonstrated in this study may be an additional contributing factor to protect the myocardium from inflammatory cell injury. Inhibition of MMP-2 by Dz13 is consistent with previous studies, which indicate that MMP-2 is a c-Jun dependent gene 20, 21 and Jun proteins regulate MMP-2 transcription. 35 LV remodeling and myocardial dysfunction after M/IR injury are mediated by MMPs, particularly MMP-2. 19, 26 Dz13 inhibited the presence of C3-, C3aR-, and Mac-1-positive cells in the injured myocardium. The primary target of Dz13, c-Jun, is an upstream regulator of effector genes, such as ICAM-1, controlling the complex process of M/IR injury. Strategies targeting c-Jun therefore offer the advantage of blocking parallel gene expression cascades. The need for this in M/IR injury is underlined by the lack of measurable clinical effect of the C5 inhibitor, pexelizumab, on infarct size in patients with ST-elevation MI undergoing primary percutaneous coronary intervention. 36, 37 That said, whether Dz13 suppression of inflammatory cell infiltration is the cause of reduced infarct size, or that DNAzyme inhibits leukocyte emigration secondary to its inhibition of infarction, in definitive terms remains to be seen.
Apoptosis accounts for myocardial death after coronary occlusion. 38 Neutrophil-mediated myocardial injury can induce necrotic as well as apoptotic cardiomyocyte death. 39 That Dz13 inhibits TUNEL ϩ staining in the M/IR-injured myocardium is supported by previous reports that AP1 can serve as a proapoptotic transcription factor. 40 Peroxynitrite, a highly reactive oxygen species, is a major cause of injury after M/IR and stimulates apoptosis. 41 Nitrotyrosine is a marker of peroxynitrite. 30 Dz13 inhibition of myocardial nitrotyrosine levels further demonstrates the utility of this DNAzyme for the prevention of apoptosis and reduction in infarct size.
That c-Jun is poorly expressed in the myocardium, but is inducible by M/IR, is consistent with its activation from a state of poor expression in other vascular settings such as normal carotid artery, 42 retina, 2 lung, 2 joint, 2 and venular microvasculature. 2 This makes c-Jun an ideal drug target because it is expressed in pathological settings and targeted interventional approaches should minimize the possibility of interfering with normal cellular functions. In the present model, cell death and myocardial inflammation is apparent 24 hours post-M/IR, 43 whereas fibrosis becomes apparent later. 44, 45 Dz13 did not reduce interstitial fibrosis despite its inhibition of infarct size and suppression of myocardial inflammation. Here we demonstrate Dz13-mediated reduction of infarct size after the DNAzyme was administered either at the commencement of ischemia or at the time of reperfusion. Although the physical size of the animals used here precluded intracoronary administration, in the clinical situation, Dz13 may be administered locally at the time of primary percutaneous coronary intervention or thrombolytic therapy.
In conclusion, this study demonstrates that strategies targeting c-Jun may be useful to reduce M/IR injury in a local delivery setting. A single dose of IM-injected Dz13 results in a significant reduction in infarct size and improved myocardial function. Dz13 suppressed c-Jun, ICAM-1, and MMP-2 expression in vascular endothelium and reduced infiltration of C3-, C3aR-, and Mac-1-positive cells in the injured myocardium.
